Related Experiment Video
Updated: Jan 16, 2026
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Advances in Multimodality Management of Localized Non-Small Cell Lung Cancer
Sushma Jonna1, Jowan Al-Nusair2, Giordano F Cittolin Santos3,4
1Division of Oncology, Durham Veterans Affairs Hospital, Durham, North Carolina.
Abstract:
Lung cancer represents the most common cause of cancer-related mortality globally, with non-small cell lung cancer (NSCLC) comprising the vast majority of cases. Outcomes for stage II-III NSCLC remain suboptimal due to late presentation, biological heterogeneity, and limited efficacy of traditional therapies. Recent advances have reshaped the therapeutic landscape, with immunotherapy and targeted treatments now integrated into the management of resectable NSCLC. Landmark trials such as CheckMate 816 demonstrated improved event-free and overall survival with neoadjuvant chemoimmunotherapy approaches. Similarly, adjuvant targeted therapies such as osimertinib and alectinib have shown benefit in patients with EGFR and ALK alterations, respectively. This review provides an overview of evolving diagnostic strategies, highlights pivotal clinical trials, and explores multidisciplinary treatment approaches across stages I to III NSCLC. We also address key challenges including optimal treatment sequencing, patient selection, and duration of therapy. As clinical trial data continue to mature, personalized multimodal strategies guided by molecular and clinical features remain central to improving long-term outcomes in resectable NSCLC.
Insights
New treatments like immunotherapy and targeted therapies are improving outcomes for early-stage non-small cell lung cancer (NSCLC). Personalized multimodal strategies are key for better survival in resectable NSCLC.
Area of Science:
- Oncology
- Pulmonology
- Clinical Therapeutics
Background:
- Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality worldwide.
- Outcomes for stage II-III NSCLC are suboptimal due to late diagnosis and treatment resistance.
- Recent therapeutic advances include immunotherapy and targeted therapies for resectable NSCLC.
Purpose of the Study:
- To review evolving diagnostic strategies for NSCLC.
- To highlight pivotal clinical trials in NSCLC management.
- To explore multidisciplinary treatment approaches for stages I-III NSCLC.
Main Methods:
- Review of landmark clinical trials (e.g., CheckMate 816).
- Analysis of neoadjuvant chemoimmunotherapy efficacy.
- Evaluation of adjuvant targeted therapies (osimertinib, alectinib) for specific mutations (EGFR, ALK).
Main Results:
- Neoadjuvant chemoimmunotherapy improves event-free and overall survival.
- Adjuvant targeted therapies demonstrate benefit in patients with EGFR and ALK alterations.
- Multimodal strategies are crucial for improving outcomes in resectable NSCLC.
Conclusions:
- Immunotherapy and targeted treatments have transformed resectable NSCLC management.
- Personalized, multimodal strategies based on molecular and clinical features are essential.
- Addressing challenges in treatment sequencing and patient selection is vital for long-term success.
